NCT01493310View on ClinicalTrials.gov

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
Male Breast CancerRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DRUG

mifepristone

"Given orally (by mouth)~Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"

DRUG

placebo

Given orally

DRUG

nab-paclitaxel

"Given by intravenous infusion (IV)~Dose of 80 mg/m2"

Trial Locations (2)

60201

NorthShore University Health System, Evanston

60637-1470

University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT01493310 - Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer | Biotech Hunter | Biotech Hunter